



ASX ANNOUNCEMENT
Lifespot Health Limited

ASX: LSH | 1st May 2017

LSH enters \$50Bn Global Medicinal Cannabis market with world leading technology JV

- **LSH has signed an MOU with Seng Vital Germany to form 50/50 JV company Seng Vital Australia to integrate their vaporizer known as Cannamed into the BodyTel platform**
- **LSH to receive revenue from its subscription fee per user SaaS model globally**
- **Global market for cannabis treatment is \$50 Bn and growing with 600,000 users**
- **The product will be a world first to monitor dosage, time of use and user identity**
- **LSH has global rights for the use of the developed IP other than Cannamed such as the Ventolin Inhaler market for Asthma and COPD that when closely managed could save US\$19 Bn annually in the USA according to Goldman Sachs**

Lifespot Health is pleased to announce it has completed discussions and signed an MOU with Seng Vital Germany to form JV company Seng Vital Australia to integrate the company's vaporizer known as Cannamed into the BodyTel platform. LSH will receive 50% of newly formed Seng Vital Australia and provide services in the final development of the Cannamed device. When Seng Vital Australia moves to full production and market entry, LSH will receive ongoing revenue via subscription services through its SaaS model.

The Global Cannabis market is currently valued at US\$50 Bn and growing with an estimated 600,000 patients currently receiving treatment. Of the two well-known methods of cannabis consumption by inhalation, the vaporizer delivery method is deemed to have fewer health concerns than the traditional combustion process or smoking. Vaporizing also provides the means for controlled delivery of cannabis to the user.

Where Cannamed will differ from others is compliance where BodyTel will monitor not only the consumption of Cannabis both in dosage and time of use but also provide additional

clinical security via feedback in the form of a finger print scanner to determine the identity of the user is considered a world's first. The BodyTel system will then analyse and present information to carers be they clinicians, support services or family members via the iOS, android or web portal formats.

The developed IP around user compliance will be the licensed to LSH for global use in products other than Cannamed and will be far reaching as other products venture from being standalone to the e-health sector.

One such sector is the management of compliance with regards to Asthma and associated diseases that affect 500M people globally that if managed correctly could save \$19 Bn annually in the USA alone according to Goldman Sachs.

ENDS

For further information:

Mr Niv Dagan
Corporate Advisor
Peak Asset Management

Mr Stefan Schraps
Chief Executive Officer
Lifespot Health Ltd

Phone: 1300 304 460
Mobile: 0402 912 198

Phone: +49 5621 967760
Mobile: +49 172 51 69 133

About Lifespot Health Ltd.

Lifespot Health operates within the digital health sector and is focused on developing and commercializing medical diagnostic and monitoring technology, which includes the BodyTel system and the Lifespot Skin system. Lifespot Health Ltd was incorporated in 2016 and is based in Melbourne, Australia.

Our systems and applications aim to bring efficiencies in the medical system to our clients and end users, saving time and money by providing real-time medical information and recommendations.

Widespread adoption of smartphones will equip our increasingly aging society to self-cater for its medical needs by using modern telemedical systems.

In providing treatment to patients wherever they are and whenever it is needed, telemedical systems have the capacity to decrease health care costs while still improving the quality of patient care.

Our systems use modern software to combine enhanced sensor technology with self-learning algorithms, allowing patients to monitor chronic diseases and critical conditions with their smartphones.